Fulgent Genetics, Inc. (FLGT)

27.08 +0.48 (+1.80%) At close: 04:00PM EST

Fulgent Genetics, Inc.

4978 Santa Anita Avenue
Temple City, CA 91780
United States
626 350 0537
https://www.fulgentgenetics.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 1,012

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ming Hsieh	Chairman & CEO	1.66M	N/A	1956
Mr. Jian Xie	COO & President	755.73k	N/A	1966
Mr. Paul Kim	Chief Financial Officer	757.59k	N/A	1967
Dr. Han Lin Gao D.A.B.M.G., FACMG, M.D., Ph.D.	Chief Scientific Officer & Laboratory Director	630.61k	N/A	1967
Ms. Natalie Prescott	General Counsel & Chief Privacy Officer	N/A	N/A	N/A
Ms. Doreen Ng	VP of Operations & Compliance and GM of Houston Office	N/A	N/A	N/A
Mr. Jakub Sram	Vice President of Business Development & Sales	N/A	N/A	N/A
Ms. Ellen Tsui	Vice President of Human Resources	N/A	N/A	N/A
Mr. Brandon Perthuis	Chief Commercial Officer	N/A	N/A	N/A
Dr. Lawrence M. Weiss M.D.	Chief Medical Officer	N/A	N/A	1957

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.